OphthalmologyIND Stage
Diabetic RetinopathyAVD-302
Aviceda’s high affinity ligands engage with immune modulatory receptors on immune cells to diminish the activation and release of inflammatory mediators, inhibit NETosis, and other destructive pathways, and thereby decrease the biochemical drivers of diabetic retinopathy.